Outcomes with the "V" Implantation Technique vs. Standard Technique for Testosterone Pellet Therapy

Journal of Sexual Medicine

Volumn 8, Issue 12, 2011, Pages 3465-3470

  Conners, William ^a   Flinn, Kevin ^a   Morgentaler, Abraham ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Hypogonadism; Outcomes; Subcutaneous testosterone pellet implant; Testopel; Testosterone

Indexed keywords

ANTICOAGULANT AGENT; TESTOSTERONE;

ADULT; ANDROGEN DEFICIENCY; ARTICLE; DRUG IMPLANT; DRUG PELLET; DRUG WITHDRAWAL; FOLLOW UP; HEMATOMA; HUMAN; HYPOGONADISM; IMPLANTATION; INFECTION; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PAIN; PELLET EXTRUSION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURGICAL TECHNIQUE; TESTOSTERONE BLOOD LEVEL; TREATMENT OUTCOME;

EID: 82955187498     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2011.02441.x     Document Type: Article

References (25)

1. Morales A, Heaton J, Carson C. Andropause: A misnomer for a true clinical entity. J Urol 2000;163:705-12.
2. Zitzmann M, Faber S, Nieschlag E. Association of specific symptoms and metabolic risks with serum testosterone in older men. J Clin Endocrinol Metab 2006;91:4335-43.
3. Kapoor D, Goodwin E, Channer K, Jones T. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol 2006;154:899-906.
4. Laaksonen D, Niskanen L, Punnonen K, Nyyssonen K, Tuomainen T, Valkonen V, Salonen R, Salonen J. Testosterone and sex hormone binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 2004;27:1036-41.
5. Meier C, Nguyen T, Handelsman D, Schindler C, Kushnir M, Rockwood A, Meikle A, Center J, Eisman J, Seibel M. Endogenous sex hormones and incident fracture risk in older men: The Dubbo Osteoporosis Epidemiology Study. Arch Intern Med 2008;168:47-54.
6. Rhoden E, Morgentaler A. Symptomatic response rates to testosterone therapy and the likelihood of completing 12 months of therapy in clinical practice. J Sex Med 2010;7:277-83.
7. Bhasin S, Bremner W. Clinical review: Emerging issues in androgen replacement therapy. J Clin Endocrinol Metab 1997;82:3-8.
8. Yassin A, Haffejee M. Testosterone depot injection in male hypogonadism: A critical appraisal. Clin Interv Aging 2007;2:577-90.
9. Margo K, Winn R. Testosterone treatments: Why, when and how? Am Fam Physician 2006;73:1591-8.
10. Seftel A. Testosterone replacement therapy for male hypogonadism: Part III. Pharmacologic and clinical profiles, monitoring, safety issues, and potential future agents. Impotence 2007;19:2-24.
11. Murphy M, Carmichael A. Transdermal drug delivery systems and skin sensitivity reactions: Incidence and management. J Clin Dermatol 2000;1:361-8.
12. Musel A, Warshaw E. Cutaneous reactions to transdermal therapeutic systems. Dermatitits 2006;17:109-22.
13. Cavender R, Fairall M. Precocious puberty secondary to topical testosterone transfer: A case report. J Sex Med 2011;8:622-6.
14. Srinivas-Shankar U, Wu F. Drug insight: Testosterone preparations. Nat Clin Pract Urol 2006;3:653-65.
15. Westaby D, Ogle S, Paradinas F, Randell J, Murray-Lyon I. Liver damage from long-term methyltestosterone. Lancet 1977;2:262-3.
16. Mazer N, Bell D, Wu J, Fischer J, Cosgrove M, Eilers B. Comparison of the steady-state pharmacokinetics, metabolism, and variability of a transdermal testosterone patch versus a transdermal testosterone gel in hypogonadal men. J Sex Med 2005;2:213-26.
17. Kaminetsky J, Moclair B, Herman M, Sand M. A phase IV prospective evaluation of the safety and efficacy of extended release testosterone pellets for the treatment of male hypogonadism. J Sex Med 2011;8:1186-96.
18. Cavender R, Fairall M. Subcutaneous testosterone pellet implant therapy for men with testosterone deficiency syndrome: A single-site retrospective safety analysis. J Sex Med 2009;6:3177-92.
19. Cavender R. Subcutaneous testosterone pellet implantation procedure for treatment of testosterone deficiency syndrome. J Sex Med 2009;6:21-4.
20. McCullough A, Khera M, Hellstrom W, Morgentaler A. Abstract #8, Sexual Medicine Society of North America Winter Scientific Meeting. 2009.
21. Handelsman D, Mackey M, Howe C, Turner L, Conway A. An analysis of testosterone implants for androgen replacement therapy. Clin Endocrinol 1997;47:311-6.
22. Jockenhovel F, Vogel E, Kreutzer M, Reinhardt W, Lederbogen S, Reinwein D. Pharmacokinetics and pharmacodynamics of subcutaneous testosterone implants in hypogonadal men. Clin Endocrinol 1996;45:61-71.
23. Kelleher S, Howe C, Conway A, Handelsman D. Testosterone release rate, duration of action of testosterone pellet implants. Clin Endocrinol 2004;60:420-8.
24. Kelleher S, Turner L, Howe C, Comway A, Handelsman D. Extrusion of testosterone pellets: A randomized controlled clinical study. Clin Endocrinol 1999;51:469-71.
25. Kelleher S, Conway A, Handelsman D. Influence of implantation site and track geometry on the extrusion rate and pharmacology of testosterone implants. Clin Endocrinol 2001;55:531-6.